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Abstract 
Background 
Pelvic floor muscle training (PFMT) is a commonly used physical therapy for women with urinary 
incontinence (UI). 
Objectives 
To determine the effects of PFMT for women with UI in comparison to no treatment, placebo or 
other inactive control treatments. 
Search Methods 
Cochrane Incontinence Group Specialized Register, (searched 15 April 2013). 
Selection Criteria 
Randomized or quasi-randomized trials in women with stress, urgency or mixed UI (based on 
symptoms, signs, or urodynamics). 
 
Data Collection and Analysis 
At least two independent review authors carried out trial screening, selection, risk of bias 
assessment and data abstraction. Trials were subgrouped by UI diagnosis. The quality of 
evidence was assessed by adopting the (GRADE) approach. 
 
Results 
Twenty-one trials (1281 women) were included; 18 trials (1051 women) contributed data to the 
meta-analysis. In women with stress UI, there was high quality evidence that PFMT is associated 
with cure (RR 8.38; 95% CI 3.68 to 19.07) and moderate quality evidence of cure or 
improvement (RR 17.33; 95% CI 4.31 to 69.64). In women with any type of UI, there was also 
moderate quality evidence that PFMT is associated with cure (RR 5.5; 95% CI 2.87–10.52), or 
cure and improvement (RR 2.39; 95% CI 1.64–3.47). 
 
Conclusions 
The addition of seven new trials did not change the essential findings of the earlier version of 
this review. In this iteration, using the GRADE quality criteria strengthened the 
recommendations for PFMT and a wider range of secondary outcomes (also generally in favor of 
PFMT) were reported. 
 
 
BACKGROUND 
Pelvic floor muscle training (PFMT) consists of a programme of repeated contractions and 
relaxations of the pelvic floor muscles taught and supervised by a health professional.[1] PFMT 
is the most commonly used physical therapy for women with stress urinary incontinence 
(SUI).[2] It is sometimes also recommended for mixed urinary incontinence (MUI) and, less 
commonly in isolation, for urgency urinary incontinence (UUI).[2] 
The biological rationale for PFMT in women with SUI is twofold. Firstly, an intentional, effective 
pelvic floor muscle contraction (lifting the pelvic floor muscles in a upward and forward 
direction) prior to and during effort or exertion clamps the urethra and increases the urethral 
pressure, preventing urine leakage.[3] Secondly, the bladder neck receives support from strong, 
toned pelvic floor muscles (resistant to stretching), thereby limiting its downward movement 
during effort and exertion, thus preventing urine leakage.[4-6] 
PFMT could also potentially be used in the management of UUI. The biological rationale is based 
on Godec's observation that a detrusor muscle contraction can be inhibited by a pelvic floor 
muscle contraction induced by electrical stimulation.[7] After inhibiting the urgency to void, the 
woman can reach the toilet in time to avoid urine leakage. 
Earlier Cochrane systematic reviews of PFMT[8-10] and other published systematic reviews of 
PFMT[11-16] are out-dated with the publication of new trials; all prior reviews noted the 
relatively few data available for analysis and considerable clinical heterogeneity in the 
studies.[8-16] There is sufficient uncertainty about the effects of PFMT, particularly the size of 
effect, to suggest that continuing to update earlier Cochrane reviews is warranted. Further, 
evidence grading standards have changed. The present review is a major update of the 2010 
Cochrane systematic review by the same principal authors. 
 
OBJECTIVES 
To determine the effects of PFMT for women with urinary incontinence in comparison to no 
treatment, placebo or sham treatments, or other inactive control treatments. 
 
METHODS AND SEARCH METHODS FOR IDENTIFICATION OF STUDIES 
See full version of the Cochrane systematic review. 
 
RESULTS 
Description of Studies 
The search produced 704 records, from which 54 potentially relevant full-text articles were 
retrieved. Thirty-four reports of 21 trials met the inclusion criteria. See Figure 1. 
 Figure 1. PRISMA Study flow diagram. 
 
 
 
Included Studies 
Twenty-one trials involving 1,281 women (665 PFMT, 616 controls) were included, 15 of which 
were included in the previous version of the review[8]; Eighteen trials (1,051 women) 
contributed data to the meta-analysis, but three trials contained no data usable for the pooled 
analysis.[17-19] Twelve trials contributed to the analysis of primary outcomes.[20-31] One trial 
from the previous review was excluded because it was considered to be confounded by the 
choice of sham.[32] Further details are provided in the full version of the Cochrane review. 
Participants 
All the women had urinary incontinence. Based on diagnosis, the subgroups used in the analysis 
were: SUI (15 trials),[17, 18, 20, 22-24, 27-31, 33-35, 37] amalgam of urinary incontinence 
diagnoses (six trials).[19, 21, 25, 26, 36, 38] No trial had participants with UUI or MUI only. 
Interventions 
Three trials gave no details of the PFMT programme used.[17, 22, 35] Of the 18 remaining trials, 
13 stated that a correct voluntary PFM maximal contraction was confirmed prior to training 
using either vaginal, rectal or physical examination.[18-21, 27, 29-31, 33, 34, 36-38] Three trials 
reported that participants were taught a voluntary PFM maximal contraction but did not say 
how.[23-25] The individual characteristics of each exercise program (that is the number of 
voluntary pelvic floor muscle contractions; duration of hold; duration of rest; number of sets per 
day; types of contraction strength; endurance; coordination; body position; and adherence 
strategies) are detailed in the full Cochrane review. 
Control interventions included no treatment,[17, 18, 26, 28, 29, 31, 33-38] placebo drug,[21] 
and sham electrical stimulation.[22] Inactive control treatments comprised use of an anti-
incontinence device,[20] advice on incontinence pads,[27] motivational phone calls once per 
month,[30] advice on simple lifestyle alterations,[19, 25] general education class (cognitive 
function, osteoporosis and oral hygiene),[24] and refraining from special exercises aiming to 
increase muscle strength, to reduce body mass index (BMI) or to improve dietary habits.[23] 
Outcomes 
Overall there was no consistency in the choice of outcome measures by trialists. This limited the 
possibilities for considering together the results from individual trials. Three eligible trials did 
not contribute any data to the main analyses because they did not report any pre-specified 
outcome of interest or they did not report their outcome data in a usable way (e.g., mean 
without a measure of dispersion, P values without raw data).[17-19] 
 
Primary outcome measures: Cure, and cure and improvement 
Many different scales were used to measure participant reported symptomatic cure or 
improvement. These included Likert scales, visual analogue scales, and percent reduction in 
symptoms. Whatever the scale, data were included in the formal comparisons when the trialists 
stated the number of women who perceived they were cured or improved (as defined by the 
trialists) after treatment. Where more than one level of improvement was reported (e.g., much 
better and somewhat better), data for the greater degree of improvement was entered in the 
comparison. It was thought, this was more likely to capture those who had improvement that 
was clinically important. As some trial reports did not differentiate cure from improvement, two 
measures (cure only, and cure or improvement) were used so that important data were not lost. 
The following definitions were used by the trialists. Participant reported cure comprised: 
 no urine loss or ‘dry'.[21, 24] 
 ‘incontinence is now unproblematic'.[20] 
 no leakage in a urinary diary.[22, 23, 25] 
  
Participant reported cure or improvement was defined as: 
 much better and somewhat better.[26] 
 ‘75% or more perceived improvement'.[21] 
 ‘dry' or ‘improved'.[27] 
 ‘continent' or ‘almost continent'.[20] 
Primary outcome measures: Symptom and condition specific quality of life measures 
Seven trials used psychometrically robust questionnaires for assessment of incontinence 
symptoms or the impact of these symptoms on quality of life or both (e.g., B-FLUTS, KING'S 
HEALTH questionnaire, I-QOL).[20, 28-31, 38] 
Risk of Bias in Included Studies 
Due to brevity of reporting, it was difficult to assess the two trials that were published as 
conference abstracts.[17, 35] Seven trials had fewer than 25 women per comparison group,[18, 
22, 26, 33, 35, 36, 38] 10 included 25–50 per group[17, 20, 23, 24, 27-30, 34, 37] and three had 
more than 50 women per group.[19, 21, 25] Bidmead et al. randomized participants in a 2:1 
ratio, with 40 in the PFMT group and 20 as controls.[17] Five trials, including four recent ones, 
reported an a priori power calculation.[20, 23, 25, 30, 38] Risk of bias assessment is illustrated in 
Figure 2 and fully described in the complete Cochrane review. 
 Figure 2. 
Summary of risk of bias analysis. 
 
Effects of Interventions 
All primary and secondary outcomes are presented in full (including forest plots) in the 
complete Cochrane review. 
 
Primary Outcome Measures 
Cure 
Six trials reported data on cure only and the confidence intervals in all six trials were wide. All 
trials found that PFMT women were statistically significantly more likely to report cure (Table I). 
In the four trials with women with SUI alone, PFMT women were eight times more likely to 
report cure than controls (46/82 (56.1%) versus 5/83 (6.0%), RR 8.38, 95% CI 3.68–19.07).[20, 
22-24] 
 
Table I. Forest Plot for Cure in PFMT Versus no Treatment, Placebo or Control 
 
The subgroup of three trials representing an amalgam of incontinence types (including one trial 
that also presented data separately for SUI alone – see above)[24] showed individual effects 
favoring PFMT and a statistically significant pooled result favoring PFMT (50/144 (34.7%) versus 
1/146 (0.6%), RR 5.34, 95% CI 2.78–10.26).[21, 24, 25] There was statistical heterogeneity and 
the more conservative random-effects model still favored PFMT (RR 7.50, 95% CI 1.03–54.63). 
Visual inspection of the forest plot suggested a smaller effect size in Burgio et al. while the effect 
size appeared similar in the two remaining trials.[21] A possible explanation of this difference in 
treatment effect may come from the percentage of women with urgency symptoms, which was 
higher in the Burgio trial than in the two others. 
 
Cure or improvement 
Four trials contributed outcome data for cure or improvement (Table II).[20, 21, 26, 27] 
Similarly, all four reported that PFMT was better than control. In two trials of SUI only,[20, 27] 
PFMT women were 17 times more likely to report cure or improvement than controls (32/58 
(55.2%) versus 2/63 (3.2%), RR 17.33, 95% CI 4.31–69.64); and in two other trials (range of 
diagnoses),[21, 26] PFMT women were twice as likely to report cure or improvement than 
controls (58/86 (67.4%) versus 23/80 (28.7%), RR 2.39, 95% CI 1.64–3.47). 
Table II. Forest Plot for Cure and Improvement in PFMT Versus no Treatment, Placebo or 
Control  
 
Symptom and condition-specific quality of life 
Three out of four incontinence specific quality of life domains (King's Health Questionnaire 
(severity), King's Health Questionnaire (physical limitation), and number of women with 
interference with life due to UI after treatment) were in favor of PFMT. In the fourth domain 
(King's Health Questionnaire [Incontinence impact]) there was statistical heterogeneity; 
although, the average effect for all trials favored PFMT, when a random-effects model was used, 
the findings did not statistically significantly support PFMT. Visual inspection of the forest plot 
suggested a smaller effect size in Pereira et al. while the effect size appeared similar in the two 
remaining trials.[31] Further details and forest plots are provided in the full version of the 
Cochrane review. 
Secondary Outcome Measures 
Cure at up to one year 
There was limited information from two small to moderate quality trials which indicated that 
the benefit of PFMT seemed to persist (after treatment stopped) for up to a year in both women 
with SUI only (14/26 (53.8%) versus 0/25 (0%), RR 27.93, 95% CI 1.75–444.45)[34] and those 
with urinary incontinence (all types) (23/59) (38.9%) versus 1/61 (1.6%), RR 23.78, 95% CI 3.32–
170.49)[25]. The width of the CIs means considerable imprecision in estimating longer term 
effect. 
Patient perceived satisfaction 
In trials which included women with SUI alone,[20, 30] PFMT women were five times more likely 
to be satisfied with the intervention than controls (36/51 (70.6%) versus 7/54 (12.9%), RR 5.32, 
95% CI 2.63–10.74). In the one trial with women with UUI or MUI, PFMT, women were three 
times more likely to be satisfied with the intervention than the controls (45/58 (77.6%) versus 
14/50 (28.0%), RR 2.77, 95% CI 1.74–4.41).[21] In contrast, women in the control groups were 
more likely to seek further treatment. 
 
Number of leakage episodes in 24 hr 
SUI women doing PFMT experienced one fewer leakage episodes in 24 hr compared to controls 
(MD −1.21, 95% CI −1.52 –−0.89).[20, 27, 30, 37] Similarly, those with UUI or MUI experienced 
about one fewer leakage episode per 24 hr compared to controls (MD −0.80, 95% CI −1.26 –
−0.34).[21] 
 
Short (up to one hour) pad test measured as grams of urine 
Four trials reported urine loss on short pad tests in SUI women[20, 30, 31] and one in women 
with urinary incontinence (type unspecified).[36] Women with SUI in the PFMT groups lost 
significantly less urine; the comparison showed statistically significant heterogeneity but the 
finding still favored PFMT if a random-effects model was used (MD −13.22, 95% CI −26.36 –
−0.09). Yoon[36] reported that PFMT women loss less urine than controls but with wide CIs that 
included no difference (MD −5.1, 95% CI −11.2–1.0). 
 
Number of voids per day 
Women in the incontinence (all types subgroup) reported about two and a half fewer voids per 
day than controls (MD −2.56, 95% CI −3.65 –−1.48).[26, 36] 
 
Sexual function 
One trial[20] in SUI women suggested that sexual function was improved by PFMT, specifically in 
reduction of urine leakage during intercourse (4/20 (20.0%) versus 13/25 (52.0%); RR 0.38, 95% 
CI 0.15–1.00). 
Adherence 
Of those who measured adherence, attendance at treatment sessions was generally good, and 
women were also motivated to practice their pelvic floor exercises during the intervention 
period. Long-term adherence (maintenance of home PFMT after treatment ends) was seldom 
reported. It was therefore not possible to assess the interaction between effect size and the 
adherence. 
 
Adverse effects 
Four trials specifically mentioned adverse events, and three did not report any in the PFMT 
group.[20, 21, 30] Lagro–Janssen was the only trial to report adverse events with PFMT.[27] and 
'not wanting to be continuously bothered with the problem' (two participants). 
Need for further treatment and socioeconomics 
The need for further treatment such as incontinence surgery or drugs was scanty. None of the 
included trials reported on costs of interventions, cost effectiveness of interventions (formal 
economic analysis or cost utility) or resource implications. 
Grading of Recommendations Assessment, Development and Evaluation (GRADE) quality of 
evidence 
GRADE summary of findings tables were prepared separately for women with SUI at baseline 
(Table III) and for women with all types of urinary incontinence (SUI, UUI, MUI) (Table IV). Only 
'Participant perceived cure – stress urinary incontinence' was rated as high quality evidence 
using the GRADE approach, and the strength of all other findings was reduced based on 
evidence quality. 
Table III. PFMT Versus no Treatment, Placebo or Control for Urinary Incontinence in Women (SUI) 
PFMT versus no treatment, placebo or control for urinary incontinence in women                                                   
1. *The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence 
interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
2. CI: Confidence interval; RR: Risk ratio. 
3. GRADE Working Group grades of evidence. 
4. High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
5. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
6. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. 
7. Very low quality: We are very uncertain about the estimate. 
8. a Not applicable. Fewer than 10 trials. 
9. b Random sequence generation and allocation concealment judge to be high risk in1/2 trials (Lagro–Janssen 1991). 
c Random sequence generation and allocation concealment is unclear in all trials taking part in meta-analysis. 
d Results are inconsistent. 
e Random sequence generation and allocation concealment judge to be high risk in1 trial (Lagro–Janssen 1991). 
f Random sequence generation and allocation concealment is unclear in 1/3 trials (Periera 2011). 
Patient or population: women with stress urinary incontinence Intervention: PFMT versus no treatment, placebo or control 
Outcomes Illustrative comparative risks* (95% CI) Relative 
effect 
(95% CI) 
No of 
Participants 
(studies) 
Quality of 
the 
evidence 
(GRADE) 
Comments 
PFMT versus no treatment, placebo or control for urinary incontinence in women                                                   
 
Assumed risk Corresponding risk 
    
Control PFMT versus no treatment, 
placebo or control 
Participant perceived cure – 
stress urinary incontinence 
Study population RR 8.38 
(3.68–
19.07) 
165 (4 
studies) 
⊕⊕⊕⊕ 
higha 
  
 
60/1000 505/1000 (222/1000) 
    
Participant perceived cure 
or improvement after 
treatment – stress urinary 
incontinence 
Study population RR 17 
(4.25–
67.95) 
121 (2 
studies) 
⊕⊕⊕⊝ 
moderatea, 
b 
  
 
32/1000 540/1000 (135–1000) 
    
Quality of life (King's Health 
Questionnaire/Incontinence 
impact after treatment) – 
stress urinary incontinence 
  The mean quality of life 
(King's health 
questionnaire/incontinence 
impact after treatment) – 
stress urinary incontinence 
in the intervention groups 
was 11.76 lower (20.83–
2.69 lower) 
  145 (3 
studies) 
⊕⊝⊝⊝ 
very lowa, 
c, d 
  
Number of leakage 
episodes in 24 hr – stress 
urinary incontinence 
  The mean number of 
leakage episodes in 24 hr – 
stress urinary incontinence 
in the intervention groups 
was 1.21 lower (1.52–0.89 
lower) 
  253 (4 
studies) 
⊕⊕⊕⊝ 
moderatea, 
e 
  
PFMT versus no treatment, placebo or control for urinary incontinence in women                                                   
Short (up to one hour) pad 
test measured as grams of 
urine – stress urinary 
incontinence 
  The mean short (up to one 
hour) pad test measured as 
grams of urine – stress 
urinary incontinence in the 
intervention groups was 
13.22 lower (26.36–0.09 
lower) 
  150 (3 
studies) 
⊕⊕⊕⊝ 
moderatea, 
f 
  
Treatment adherence – not 
reported 
See 
comment 
See comment Not 
estimable 
– See 
comment 
  
Formal economic analysis – 
not reported 
See 
comment 
See comment Not 
estimable 
– See 
comment 
  
 
Table IV. PFMT Versus no Treatment, Placebo or Control for Urinary Incontinence in Women (All Types) 
PFMT versus no treatment, placebo or control for urinary incontinence in women 
1. *The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% 
confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). 
2. CI: Confidence interval; RR: Risk ratio. 
3. GRADE Working Group grades of evidence. 
4. High quality: Further research is very unlikely to change our confidence in the estimate of effect. 
5. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. 
6. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the 
estimate. 
7. Very low quality: We are very uncertain about the estimate. 
8.           a Allocation concealment is unclear in Burgio 1998 which is the biggest trial. 
b Not applicable. Fewer than 10 trials. 
c Allocation concealment is unclear in both the trials. 
d Allocation concealment is unclear in Burgio 1998. 
e Not applicable as there is only one trial. 
f Random sequence generation and allocation concealment judge to be unclear in 1 trial which reported this outcome. 
g Results are imprecise. 
PFMT versus no treatment, placebo or control for urinary incontinence in women 
Patient or population: women with urinary incontinence (all types) Intervention: PFMT versus no treatment, placebo or control 
Outcomes Illustrative comparative risks* 
(95% CI) 
Relative 
effect (95% 
CI) 
No of 
Participants 
(studies) 
Quality of 
the 
evidence 
(GRADE) 
Comments 
Assumed 
risk 
Corresponding 
risk 
Control PFMT versus 
no treatment, 
placebo or 
control 
Participant perceived cure – 
urinary incontinence (all 
types) 
Study population RR 5.5 
(2.87/10.52) 
301 (3 
studies) 
⊕⊕⊕⊝ 
moderatea, 
b 
  
57/1000 315/1000 
(165–603) 
Participant perceived cure 
or improvement after 
treatment – urinary 
incontinence (all types) 
Study population RR 2.35 
(1.62–3.39) 
166 (2 
studies) 
⊕⊕⊕⊝ 
moderateb,c 
  
288/1000 676/1000 
(466–975) 
Quality of life (King's Health 
Questionnaire/Incontinence 
impact after treatment)—
urinary Incontinence (all 
types)—not reported 
See 
comment 
See comment Not 
estimable 
– See 
comment 
  
Number of leakage 
episodes in 24 hr – urinary 
  The mean 
number of 
  125 (1 ⊕⊕⊕⊝ 
moderated, 
  
PFMT versus no treatment, placebo or control for urinary incontinence in women 
incontinence (all types) leakage 
episodes in 24 
hr – urinary 
incontinence 
(all types) in 
the 
intervention 
groups was 
0.8 lower 
(1.26–0.34 
lower) 
study) e 
Short (up to one hour) pad 
test measured as grams of 
urine – urinary 
incontinence (all types) 
  The mean 
short (up to 
one hour) pad 
test measured 
as grams of 
urine – urinary 
incontinence 
(all types) in 
the 
intervention 
groups was 
5.1 lower 
(11.16 lower – 
0.96 higher) 
  25 (1 study) ⊕⊕⊝⊝ 
lowc, f, g 
  
Treatment adherence – not 
reported 
See 
comment 
See comment Not 
estimable 
– See 
comment 
  
Formal economic analysis – 
not reported 
See 
comment 
See comment Not 
estimable 
– See 
comment 
  
 
DISCUSSION 
Twenty-one trials involving 1,281 women (665 PFMT, 616 controls) were included; 18 trials 
(1,051 women) contributed data to the meta-analysis. The results were consistent for most of 
the outcomes, favoring PFMT over control. The only outcome that was consistently not different 
between the experimental and control conditions was generic quality of life (data not reported 
here – see full Cochrane review); such measures may not be sensitive enough to pick up changes 
due to improvement in urinary incontinence. The main reasons for downgrading the quality of 
the evidence in the GRADE summary of findings table (Tables III and IV) were: 
 
 Random sequence generation and allocation concealment was high risk or 
unclear in some trials; 
 Results were inconsistent for the quality of life outcomes; 
 Results were imprecise (heterogeneity due to variation in results, although 
these were generally in favor of PFMT). 
 
Other limitations, noted in prior systematic reviews, remain. The trials were generally of small or 
moderate size, with insufficient detail of participant selection and a lack of clear description of 
the PFMT programs. There was considerable variation in interventions used, study populations, 
and outcome measures. There were no trials of women with UUI only or MUI only. Only short-
term adherence data were reported, and were predominantly clinic/class attendance rates 
which may not reflect home exercise adherence. Socioeconomic data also remain scanty. 
Another problem was the lack of long-term follow-up. Maintaining the effects of randomization 
in longer term follow-up is problematic because it is often confounded by the offer of treatment 
to women in the control arms; however, longer term follow-up of the whole cohort would 
potentially yield some useful data about duration of treatment effect after supervised treatment 
ends. 
 
CONCLUSION 
Implications for Practice 
Based on the data available, PFMT is better than no treatment, placebo drug, or inactive control 
treatments for women with stress urinary incontinence or urinary incontinence (all types), but 
there was no information about women with UUI alone or MUI alone. Women treated with 
PFMT were more likely to report cure or improvement, report better quality of life, have fewer 
leakage episodes per day, and have less urine leakage on short office-based pad tests than 
controls. Women were also more satisfied with the active treatment, and according to a single 
moderate size trial with low risk of bias, their sexual outcomes were better. Overall, there is 
support for the widespread recommendation that PFMT be included in first line conservative 
management programmes for women with stress incontinence or in groups of women with a 
variety of types of incontinence. The limited nature of follow-up beyond the end of treatment in 
the majority of the trials means that the long-term outcomes of use of PFMT remain uncertain. 
Implications for Research 
Although the quality of recent trials has improved, most of the data in this review come from 
small to moderate sized trials of moderate methodological quality. In planning future research, 
trialists are encouraged to consider the following. 
 The choice of primary outcomes important to women, the size of a clinically 
important effect, and subsequent estimation of sample size. 
 Detailed reporting of PFMT exercise programmes (available as supplementary 
information online if necessary). 
 Measuring adherence and reporting any adherence strategies used. 
 The need for further treatment such as with pessaries, surgery or drugs. 
 The duration of follow-up especially long term. 
 The reporting of economic/cost data or formal economic analysis. 
REFERENCES 
1. Morris M. Maternity and post-operative exercises. London: William Heinemann Ltd. 1936. 5–
11, 60–65. 
2. Moore K, Dumoulin C, Bradley C, et al. Adult Conservative Management. In. In: Abrams PH 
Cardoza L Khoury AE Wein A editor., International Consultation on Urinary Incontinence. 
Plymbridge United Kingdom: Health Publication Ltd. 2013. 1112–229. 
3. DeLancey JOL. Structural aspects of urethrovesical function in the female. Neurourol 
Urodynam 1988; 7:509–19. 
4. Bø K. Pelvic floor muscle training is effective in treatment of female stress urinary 
incontinence, but how does it work?. Int Urogynecol J Pelvic Floor Dysfunct 2004; 15:76–84. 
5. DeLancey JOL. Anatomy and mechanics of structures around the vesical neck: How vesical 
neck position might affect its closure. Neurourol Urodynam 1988; 7:161–162. 
6. Peschers UM, Vodusek DB, Fanger G, et al. Pelvic muscle activity in nulliparous volunteers. 
Neurourol Urodynam 2001; 20:269–75. 
7. Godec C, Cass AS, Ayala GF. Bladder inhibition with functional electrical stimulation. Urology 
1975; 6:663–666. 
8. Dumoulin C, Hay-Smith J. Pelvic floor muscle training versus no treatment, or inactive control 
treatments, for urinary incontinence in women. Cochrane Database Syst Rev 2010. doi: 
10.1002/14651858.CD005654.pub2. 
9. Hay-Smith EJC, Bø K, Berghmans LCM, et al. Pelvic floor muscle training for urinary 
incontinence in women (Cochrane Review). Cochrane Database Syst Rev 2002. doi: 
10.1002/14651858.CD001407. 
10. Hay-Smith J, Dumoulin C. Pelvic floor muscle training versus no treatment, or inactive 
control treatments, for urinary incontinence in women. Cochrane Database Syst Rev 2006. doi: 
10.1002/14651858.CD005654. 
11. Berghmans LC, Hendriks HJ, Bø K, et al. Conservative treatment ofstress urinary incontinence 
in women: A systematic review of randomized clinical trials. Br J Urol 1998; 82:181–91. 
12. Berghmans LCM, Hendriks HJM, de Bie RA, et al. Conservative treatment of urge urinary 
incontinence in women: A systematic review of randomized clinical trials. BJU Int 2000; 85:254–
63. 
13. Bø K. Physiotherapy to treat genuine stress incontinence. Int Continence Surv 1996; 6:2–8. 
14. de Kruif YP, van Wegen EE. Pelvic floor muscle exercise therapy with myofeedback for 
women with stress urinary incontinence: A meta-analysis. Physiotherapy 1996; 82:107–113. 
15. Fedorkow DM. Nonsurgical management of stress urinary incontinence. J SOGC 1993; 
15:695–705. 
16. Wilson P, Bø K, Bourcie A, et al. Conservative management in women. In: Abrams P Khoury S 
Wein A editor., Incontinence. UK: Health Publication Ltd. 1999. 579–636. 
17. Bidmead J, Mantle J, Cardozo L. Home electrical stimulation in addition to conventional 
pelvic floor exercises: A useful adjunct or expensive distraction? Neurourol Urodynam 2002; 
21:372–373. 
18. Miller JM, Ashton-Miller JA, DeLancey JOL. A pelvic muscle precontraction can reduce cough-
related urine loss in selected women with mild SUI. J Am Geriatr Soc 1998; 46:870–874. 
19. Wells TJ, Mayor RD, Brink CA, et al. Pelvic floor muscle exercise: A controlled clinical trial. 
Unpublished work however portions were presented at the sixteenth annual scientific meeting 
of the American Urogynecologic Society, Seattle, October 12–15, 1995. 1999. 
20. Bø K, Talseth T, Home I. Single blind, randomised controlled trial of pelvic floor exercises, 
electrical stimulation, vaginal cones, and no treatment inmanagement of genuine stress 
incontinence in women. BMJ 1999; 318:487–93. 
21. Burgio KL, Locher JL, Goode PS, et al. Behavioral versus drug treatment for urge urinary 
incontinence in older women. JAMA 1998; 280:1995–2000. 
22. Hofbauer VJ, Preisinger F, Nurnberger N. The value of physical therapy in genuine female 
stress incontinence. [German] [Der stellenwert der physiokotherapie bei der wieblichen 
genuinen seb–inkontinenz]. Zeitschrift Fur Urologie Und Nephrologie 1990; 83:249–54. 
23. Kim H, Suzuki T, Yoshida Y, et al. Effectiveness of multidimensional exercises for the 
treatment of stress urinary incontinence in elderly community-dwelling Japanese women: A 
randomized, controlled, crossover trial. J Am Geriatr Soc 2007; 55:1932–9. 
24. Kim H, Yoshida H, Suzuki T. Effects of exercise treatment with or without heat and steam 
generating sheet on urine loss in community-dwelling Japanese elderly women with urinary 
incontinence. Geriatr Gerontol Inte 2011; 11:452–9. 
25. Kim H, Yoshida H, Suzuki T. The effects of multidimensional exercise treatment on 
community dwelling elderly Japanese women with stress, urge, and mixed urinary incontinence: 
A randomized controlled trial. Int J Nurs Stud 2011; 48:1165–72. 
26. Diokno AC, Ocampo MS, Jr, Ibrahim IA. Group session teaching of behavioral modification 
program (BMP) for urinary incontinence: a randomized controlled trial among incontinent 
women. Int Urol Nephrol 2010; 42:375–81. 
27. Lagro-Janssen TLM, Debruyne FMJ, Smits AJA, et al. Controlled trial of pelvic floor exercises 
in the treatment of urinary stress incontinence in general practice. Br J Gen Pract 1991; 41:445–
9. 
28. Beuttenmuller L, Cader SA, Macena RHM, et al. Muscle contraction of the pelvic floor and 
quality of life of women with stress urinary incontinence who underwent kinesitherapy. 
Fizjoterapia 2010; 18:35–41. 
29. Carneiro EF, Araujo Ndos, Beuttenmull S, et al. The anatomical-functional characteristics of 
the pelvic floor and quality of life of women with stress urinary incontinence subjected to 
perineal exercises [Spanish]. Actas Urol Esp 2010; 34:788–93. 
30. Castro RA, Arruda RM, Zanetti MR, et al. Single-blind, randomized, controlled trial of pelvic 
floor muscle training, electrical stimulation, vaginal cones, and no active treatment in the 
management of stress urinary incontinence. Clinics (Sao Paulo, Brazil) 2008; 63:465–472. 
31. Pereira VS, Correia GN, Driusso P. Individual and group pelvic floor muscle training versus no 
treatment in female stress urinary incontinence: a randomized controlled pilot study. Eur J 
Obstet 2011; 159:465–471. 
32. Schagen van Leeuwen, Elser JH, Freeman D, et al. Controlled trial of duloxetine alone, pelvic 
floor muscle training alone, combined treatment in women with stress urinary incontinence 
(SUI) [Abstract]. Eur Urol Suppl 2004; 3:52. 
33. Aksac B, Aki S, Karan A, et al. Biofeedback and pelvic floor exercises for the rehabilitation of 
urinary stress incontinence. Gynecol Obstet Invest 2003; 56:23–7. 
34. Henalla SM, Hutchins CJ, Robinson P, et al. Nonoperative methods in the treatment of 
female genuine stress incontinence of urine. J Obstet Gynaecol 1989; 9:222–5. 
35. Henalla SM, Millar DR, Wallace KJ. Surgical versus conservative management for post-
menopausal genuine stress incontinence of urine [abstract 87]. Neurourol Urodynam 1990; 
9:436–7. 
36. Yoon HS, Song HH, Ro YJ. A comparison of effectiveness of bladder training and pelvic 
muscle exercise on female urinary incontinence. Int J Nurs Stud 2003; 40:45–50. 
37. Burns PA, Pranikoff K, Nochajski TH, et al. A comparison of effectiveness of biofeedback and 
pelvic muscle exercise treatment of stress incontinence in older community dwelling women. J 
Gerontol 1993; 48:M167–74. 
38. Sar D, Khorshid L. The effects of pelvic floor muscle training on stress and mixed urinary 
incontinence and quality of life. J Wound Ostomy Continence Nurs 2009; 36:429–35. 
To access the final version (PDF): http://onlinelibrary.wiley.com/doi/10.1002/nau.22700/epdf 
 
